SPY742.07+0.92%QQQ662.30+0.94%BTC/USD74,480.39−0.33%DIA518.44+1.21%GLD377.62+1.37%TLT82.24+0.39%

Premium Services

Premium Services

Starling Oncology Inc

STLNNASDAQ

Trade with Public

Trade with Public

$3.62

-3.08-45.97%

Last update: Nov 9, 8:46 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Starling Oncology (STLN) Stock Price Target 2026 & Analyst Forecast - Benzinga

Starling Oncology (STLN) Stock Price Target 2026

The average analyst price target for Starling Oncology is $9.25, 138.4% above the current price. Of 4 analysts, 4 rate it Buy. Targets range from $8 to $10. The latest change came on Nov 6, 2026, when Lake Street lowered its price target on Starling Oncology from $10 to $8 and kept a Buy rating.

The Average Analyst Price Target for Starling Oncology is $9.25.

Price Target Range — 1 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$9.25Upside to Avg. PT+138.4%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Starling Oncology Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 9, 2026	BTIG	David Larsen	Maintained	Buy	$10
Nov 6, 2026	Lake Street	—	PT Cut	Buy	$10→$8
Nov 6, 2026	B. Riley Securities	Yuan Zhi	PT Cut	Buy	$11→$10
Nov 6, 2026	BTIG	David Larsen	PT Raise	Buy	$9→$10
Oct 14, 2026	Needham	Matthew Shea	PT Raise	Buy	$7→$9

Analyst Ratings News

PRO
BTIG Reiterates Buy on Starling Oncology, Maintains $10 Price Target

BTIG analyst David Larsen reiterates Starling Oncology (NASDAQ:STLN) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on Starling Oncology, Lowers Price Target to $8

Lake Street maintains Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $10 to $8.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10

B. Riley Securities analyst Yuan Zhi reiterates Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $11 to $10.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Starling Oncology, Raises Price Target to $10

BTIG analyst David Larsen maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $9 to $10.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Starling Oncology, Raises Price Target to $9

Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.

Benzinga Newsdesk